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INTRODUCTION
Fibrolamellar hepatocellular carcinoma (FL-HCC), a rare variant of conventional hepatocellular carcinoma (HCC), was first described by Edmondson in 1956 and accounts for approximately 5% of HCC cases (1, 2). The tumour is composed of large polygonal cells with large nuclei containing marginalized chromatin and prominent nucleoli and eosinophilic cytoplasm containing pale bodies, and hyaline globules, surrounded by distinctly lamellar stroma (2, 3) . It is most common in the age group between five and 35 years (3) (4) (5) (6) (7) . Some studies report a female predilection (4, 6, 8) . Generally no underlying liver disease including cirrhosis is present in FL-HCC patients and in particular no link with hepatic viruses has been established (2, (9) (10) (11) (12) . While HCC is often multifocal and metastatic at diagnosis and associated with abdominal pain, FL-HCC is reputed to present as a single, large, slow-growing, painless mass (6, 11, 13) . Serum alpha-fetoprotein (AFP) levels are almost always normal in patients with FL-HCC (2, 5). The standard treatment when possible is surgery with lymphadenectomy, as FL-HCC is associated with a high rate of lymph node metastasis and lymph nodes are common sites of first disease recurrence (11, 14, 15) . Although FL-HCC is often diagnosed at a stage that would not allow for resection of HCC, aggressive resection may result in longterm survival (11, 13) . Currently available non-surgical treatments are relatively ineffective. Earlier studies consistently reported a better prognosis of FL-HCC compared to HCC (3, 4, 9, 8, 16, 17) . However, these studies lack accompanying analyses of non-cirrhotic HCC cases, and reported better outcomes of FL-HCC in adults may be confounded by absence of cirrhosis, a separate mortality risk factor in HCC (2, 5, 6, 18) . Since the majority of reports regarding FL-HCC involves adult patients only, analysis of the paediatric experience in the SIOPEL-2 and -3 trials and treatment recommendations based on observations derived from these trials seemed warranted.
PATIENTS AND METHODS

PATIENTS
Amongst 90 HCC patients registered in the SIOPEL database, only cases with a clear distinction in histological features during pathology review were selected in order to compare two well-defined groups of pathology proven FL-HCC and HCC. Sixty-two patients with either HCC (n = 38) or FL-HCC (n = 24) were selected from the SIOPEL-2 and -3 databases for analysis. An in-depth analysis of the entire HCC group was performed separately.
SIOPEL-2 and -3 were international, prospective, cooperative clinical trials, open to registration of paediatric patients with primary liver tumours between October 1995 and May 1998 and June 1998 and December 2006, respectively (19, 20) .
PATIENT INFORMATION AT DIAGNOSIS AND PRE-TREATMENT EXTENT OF DISEASE (PRETEXT) EVALUATION
Diagnostic biopsy of the primary tumour was mandatory in children (a) younger than 6 months, (b) older than 3 years or (c) with a normal serum AFP. In all other cases biopsy was strongly recommended. Tumour extension was assessed by computed tomography (CT) or magnetic resonance imaging (MRI) for the abdomen, and X-ray and CT for the intra-thoracic lesions. Tumour stage was established with the PRE-Treatment EXTent of disease (PRE-TEXT) system, based on findings at diagnostic imaging (21, 22) . Trials were approved by the institutional review boards of participating centers. Informed consent was obtained from patients and parents according to local requirements.
TREATMENT
All HCC cases (including FL-HCC) were classified as high risk. The SIOPEL-2 and -3 high risk regimen involved alternating cycles of cisplatin (CDDP) and carboplatin/ doxorubicin (CAR-BO/DOXO; preoperatively, n = 7; postoperatively, n = 3) and delayed tumour resection (19, 20) . Patients were initially treated with alternating courses of CDDP on days 1, 29, 57 and 85 and the combination CARBO/DOXO on days 15, 43 and 71. CDDP was administered at a dose of 80 mg/m2 IV over 24 h followed by IV hydration. CARBO was given at 500 mg/m2 IV over 1 h, followed by DOXO 60 mg/m2 over 48 h. After seven courses, tumour resection was performed if feasible. After resection patients received the remaining three courses and finished treatment. If after seven courses the tumour remained unresectable, patients were treated with another three courses and, if feasible, resection was performed. For those patients who responded to chemotherapy, but whose primary tumour remained unresectable, total hepatectomy with orthotopic liver transplantation (OLT) was considered at this point. If resection or OLT was performed after 10 courses, no postoperative chemotherapy was given. In patients with initial metastatic disease, residual lesions after pre-operative chemotherapy were removed surgically, if feasible. As it became apparent during SIOPEL-1 that children with HCC had a lower response to chemotherapy than children with hepatoblastoma, clinicians were given the choice to follow the strategy as outlined above or attempt surgery first, followed by post-operative chemotherapy using a more intensive three-drug regimen (CDDP and CARBO/DOXO -'SUPERPLADO') (23) .
OUTCOME DEFINITIONS AND STATISTICAL METHODS
Main objective of the original HCC study of which the present study was derived, was to compare response and subsequent resectability between an intensive multi-agent chemotherapy regimen and earlier used chemotherapy regimens in paediatric patients with HCC. The objectives of this analysis were to compare clinical course and outcome of FL-HCC versus HCC in the SIOPEL experience and to define implications on treatment guidelines for FL-HCC. With regard to these objectives, main outcome endpoints were partial response to preoperative chemotherapy, the rate of complete resection, event free survival (EFS) and overall survival (OS). For FL-HCC, a partial response was defined as any tumour volume shrinkage. For HCC, a decrease in AFP value > 1 log below the original measurement with or without volume change was considered a partial response. Complete resection was defined as resection without microscopic residual disease of all tumour sites based on pathological findings. EFS was defined as the time interval from date of diagnosis to first occurrence of progression, relapse or death from any cause, or the date of last follow-up. OS was defined as the time interval between date of diagnosis and date of death from any cause or date of last follow-up.
Statistics of differences in patient characteristics between groups were calculated using Wilcoxon test (age and serum AFP), chi-square test (PRETEXT classification) and Fisher's exact test (all other patient characteristics). The Kaplan-Meier method was used to derive survival curves. Estimates of EFS and OS were compared at 3 years by a z-test for the comparison of proportions; the log-rank test was deemed inappropriate due to crossing curves. Multivariate proportional hazards regression was performed to evaluate prognostic factors for OS and EFS, stratified by histology. Backward elimination was used to identify a parsimonious model. All statistical evaluations were done with SAS version 9.1.
RESULTS
PATIENT AND TUMOUR CHARACTERISTICS
During SIOPEL-2 and SIOPEL-3, 62 cases of HCC could be subdivided into HCC and FL-HCC. Of these tumours, 24 (39%) had FL-HCC histology and 38 (61%) were consistent with HCC. The majority of reviewed cases developed in normal liver (n = 58, 94%). An overview of demographic and clinical characteristics is shown in Table 1 .
TREATMENT CHEMOTHERAPY
In total, 13 FL-HCC patients (54%) and 32 HCC patients (84%) had documented preoperative chemotherapy. Partial tumour response to preoperative chemotherapy occurred in four out of 13 (31%) patients with FL-HCC versus 17/32 (53%) of patients with HCC; the difference is not statistically significant (p = 0.17). Four FL-HCC patients received postoperative chemotherapy only. Detailed response data are shown in Table 2 .
SURGERY
Primary surgery was performed in eight (33%) FL-HCC and five (13%) HCC patients. A correlation between tumour size and complete resection rate or EFS/OS could not be established in these patient subgroups. Of all patients who underwent surgery, either initially or delayed, ten FL-HCC patients (42%) and seven HCC (18%) patients had a complete resection (p = 0.08). Specific data on resection are summarised in Table 3 .
OUTCOME/SURVIVAL
There is no statistically significant difference in EFS between the FL-HCC and HCC groups at 3 years follow up (22% versus 28%, p = 0.30; Fig. 1 ). Multivariate proportional hazards regression of the entire group and stratified by histology showed a trend towards lower EFS with multifocality (HR 1.74, p = 0.09) and with age above 12 years (HR 1.89, p = 0.07). OS was better for FL-HCC during the first 3 years. At 3 years, OS was 42% for FL-HCC versus 33% for HCC (p = 0.24). Forty-two per cent of patients with HCC versus 2% with FL-HCC died within 1 year. However, thereafter the Kaplan-Meier curves crossed and the FL-HCC curve reached a plateau phase lower than observed in HCC after approximately 4 years follow up (Fig. 2) . The median follow up was 43 months (range 1-117 months) in the FL-HCC group and 60 months (range 9 -114 months) in the HCC group. No significant correlation was found between potential prognostic factors and OS. Of the 23 patients who had a complete resection or an OLT, nine died (39%), whereas 34/39 (87%) of those without a documented complete resection died. 
TABLES
FIBROLAMELLAR VARIANT OF HEPATOCELLULAR CARCINOMA DOES NOT HAVE A BETTER SURVIVAL THAN CONVENTIONAL HEPATOCELLULAR CARCINOMA-RESULTS AND TREATMENT RECOMMENDATIONS FROM THE CHILDHOOD LIVER TUMOUR STRATEGY GROUP (SIOPEL) EXPERIENCE
FIGURES
Fig. 1. Kaplan-Meier estimate of event free survival (EFS) for fibrolamellar hepatocellular carcinoma (FL-HCC) group versus conventional hepatocellular carcinoma (HCC) group. EFS of FL-HCC versus HCC at 3 years follow-up was compared for
proportions by z-test; p = 0.30.
Fig. 2. Kaplan-Meier estimate of overall survival (OS) for fibrolamellar hepatocellular carcinoma (FL-HCC) group versus conventional hepatocellular carcinoma (HCC) group. OS of FL-HCC versus HCC at 3 years follow up was compared for
proportions by z-test; p = 0.24. 
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DISCUSSION
In contrast to earlier study reports, our study shows that the longterm outcome in FL-HCC patients does not differ from that of HCC patients (3, 4, 9, 8, 16, 17) . In line with this analysis, a Children's Oncology Group (COG) study found similar prognoses for the two subtypes, treated according to the same protocol (7) . Some studies claim, however, that FL-HCC has a survival advantage in high stages and transplanted cases only (13, 24) . Several other recent papers also report that FL-HCC is an aggressive tumour, which has no better outcome than HCC on behalf of tumour characteristics (2, 7, 18) .
In our study, OS in the FL-HCC group declined to reach a plateau phase lower than for HCC. As such, results from SIOPEL-1, where longer survival in the same time range for FL-HCC patients compared to HCC patients was observed, could not be reconfirmed (25) . The low number of patients with FL-HCC may play a role, as only six out of 39 HCC patients in that study had the FL-HCC variant. However, although longer survival for FL-HCC patients was found, four out of six patients with FL-HCC died, with a median survival of 15 months for all patients who died in the study.
FL-HCC and HCC should be regarded as separate entities, displaying distinctive pathological patterns and dysregulated biological pathways. Molecular markers indicative of FL-HCC (CK7, EMA, mCEA, CA19-9, EpCAM) indicate that this tumour could be derived from a precursor cell with the ability to differentiate into hepatocytes and biliary cells, unlike HCC that does not express any of these markers (14) . In contrast to HCC, FL-HCC does not show CTNNB or p53 mutations, however, high levels of Y654-b-catenin represent increased receptor tyrosine kinase signaling, potentially rendering FL-HCC susceptible to receptor tyrosine kinase targeting (26) . In a recent report, more than 75% of investigated FL-HCC's showed overexpression of the oncogene AGR2 (27) . Other potential molecular mechanisms include activation of the NF-қB signaling pathway (28) . The slow proliferative rate of stem cells and high biliary and hepatocytic differentiation phenotype of FL-HCC may explain its relative resistance to chemotherapy and radiation therapy. Nevertheless, the above-mentioned findings of molecular markers in FL-HCC may pave the way for targeted therapy.
Clinically, children with FL-HCC in this series tended to be older at diagnosis than those with HCC, in line with findings in the prospective COG study, where 90% of children with FL-HCC versus 47% with HCC were above 10 years of age (Table 1) (7) . The female predilection identified in reports of mostly adult patients was not reproduced in our paediatric series (M:F 54:46%, Table 1 ), confirming results of other paediatric and mixed paediatric/ adult series (3, 4, 6-8, 10, 12) . Similar to findings in other reports, AFP levels were low in FL-HCC cases (median 4 ng/mL; range 1-44,790 ng/mL) in comparison to HCC cases (median 211,375 ng/mL; range 1-1,700,000) (5-7, 10, 11). FL-HCC was less often multifocal than HCC (Table 1 ). The presence of satellite lesions correlated, albeit borderline, with reduced 57 EFS in the multivariate analysis of the entire group, in line with a series of 174 HCC's of which 15 were of FL-HCC histology (average age FL-HCC patients 23 ± 2.6 years), where absence of multiple tumours was significantly associated with increased survival (6) . Importantly, stage at diagnosis may have had an effect on differences in outcome between groups; HCC was more often diagnosed as PRETEXT III, IV or P+. On the other hand, FL-HCC was more frequently PRETEXT E+ (Table 1) . However, no significant correlation between any potential prognostic factors and OS was found.
In the present study, both groups were treated with the same chemotherapy regimen and there was only a borderline difference in the overall low rate of partial response to preoperative chemotherapy (31% of treated FL-HCC's versus 55% of HCC's), possibly reflecting resistance to currently used therapies in either type of histology.
FL-HCC is commonly described as more suitable for resection than HCC, and complete resection including lymph node dissection is at present the most effective treatment option (11, 13) . In contrast to findings in the large, prospective, uniformly treated COG series, our study found a higher complete resection rate in the FL-HCC group, despite a higher number of OLT in the HCC group (7). In the entire cohort, the percentage of death was much higher amongst patients who did not have a complete resection or OLT versus patients who did undergo successful surgical treatment, stressing the importance of a complete resection in either tumour type. The higher survival rate at early follow up in the FL-HCC group may have its origins in the observed higher complete resection rate. Another potential explanation for the delayed decline in survival in this group compared to the HCC group is late recurrence, a well-known feature of FL-HCC (11, 13) . The combination of an (on average) earlier stage at diagnosis and more extrahepatic intra-abdominal metastasis, together with findings of inferior longterm outcome in FL-HCC compared to HCC emphasises the importance of a radical surgical approach -resection or OLT -at the earliest opportunity in FL-HCC. Probably in children the Milano criteria should not even be taken into account (29) . Repeat resection for recurrence is strongly advocated by some, given the lack of good alternative treatment strategies and the relatively indolent tumour behaviour which may be associated with low sensitivity to other therapies (7, 11) . As repeat resection for FL-HCC has not been investigated by SIOPEL, no recommendation on this subject can be derived from this study. This is the largest available prospective study comparing FL-HCC and HCC in children. Except for data from the COG study, currently available knowledge of behaviour and treatment of this rare tumour is derived from small, mostly retrospective series, with multiple treatment modalities, inconsistent clinical detail, and varying patient age (7). Thus, comparing these studies is of limited value.
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Results from the present study confirm the conclusion of recent studies that FL-HCC does not have a more favourable prognosis than HCC (7, 18) . A long follow up is warranted given the late recurrences observed. Given the low response to chemotherapy and since longterm survival is only seen in completely resected FL-HCC patients, complete resection should be pursued whenever possible. When FL-HCC is diagnosed through biopsy, primary surgery can be performed. Multicentre prospective randomized trials are needed to test new treatment modalities and regimens toward efficacious therapies, especially in advanced disease. The COG, SIOPEL, Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) and Japanese Study for Paediatric Liver Tumours (JPLT) started the Children's Hepatic tumour International Collaboration (CHIC) Project, an international hepatic tumours database (30) . This initiative serves to identify independent prognostic factors, and allows for development of a common risk stratification system and common chemotherapy response criteria for the development of therapeutic trials. Despite its retrospective nature, this collaboration holds promise to advance our knowledge and improve treatment of FL-HCC, as its comprehensive nature may overcome the issues of low numbers in uniformly treated series of this rare but detrimental tumour.
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